Velin Dominique, Michetti Pierre
Service de Gastro-Entérologie et d'Hépatologie, CHUV, Lausanne, Suisse.
Digestion. 2006;73(2-3):116-23. doi: 10.1159/000094043.
Helicobacter pylori is a Gram-negative, spiral bacterium that colonizes the gastric mucosa of at least 50% of the world's population and plays a causative role in the development of chronic gastritis as well as in gastric and duodenal ulcers. H. pylori triggers vigorous humoral and cellular immune responses in both systemic and mucosal compartments. In spite of this response, the vast majority of infected hosts are unable to clear the infection, and it persists for decades. Although Helicobacter is tolerated by a naïve host organism, preclinical studies have demonstrated that prophylactic or therapeutic vaccinations efficiently clear Helicobacter from the stomach. The understanding of the mechanisms leading to the Helicobacter persistence or the vaccine-induced eradication of Helicobacter in animal models will help to define optimal immunization strategies for future anti-Helicobacter vaccination clinical trials.
幽门螺杆菌是一种革兰氏阴性螺旋菌,它定植于全球至少50%人口的胃黏膜中,在慢性胃炎以及胃和十二指肠溃疡的发生发展中起致病作用。幽门螺杆菌在全身和黏膜部位引发强烈的体液免疫和细胞免疫反应。尽管有这种反应,但绝大多数受感染宿主无法清除感染,感染会持续数十年。虽然未感染的宿主生物体能够耐受幽门螺杆菌,但临床前研究表明,预防性或治疗性疫苗接种可有效清除胃内的幽门螺杆菌。了解动物模型中导致幽门螺杆菌持续存在或疫苗诱导根除幽门螺杆菌的机制,将有助于确定未来抗幽门螺杆菌疫苗临床试验的最佳免疫策略。